Study guide
6.2 Psychopharmacology Mechanisms
NBME Comprehensive Basic Science Examination CBSE
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Navigation
1.1 Current Exam Facts & Administration 1.2 Content Blueprint & Physician Tasks 1.3 Scoring, Score Reports & Step 1 Readiness
2 Human Development
2.1 Embryology & Congenital Development Patterns 2.2 Normal Age-Related Findings & Well-Patient Care
3 Blood & Hematologic Disease
3.1 Hematopoiesis, RBC Disorders & Anemias 3.2 Hemostasis, Thrombosis & Coagulopathies 3.3 WBC Disorders, Leukemia & Lymphoma Mechanisms
4 Immune System
4.1 Innate & Adaptive Immunity Mechanisms 4.2 Hypersensitivity, Autoimmunity & Immunodeficiency 4.3 Transplant Immunology & Immune Pharmacology
5 Nervous System Anatomy & Disease
5.1 Neuroanatomy Localization & Pathways 5.2 Stroke, Infection, Demyelination & Trauma 5.3 Seizures, Movement Disorders & Neurodegeneration 5.4 Special Senses: Eye & Ear Mechanisms
6 Behavioral Health
6.1 Psychiatric Disorders & Diagnostic Patterns 6.2 Psychopharmacology Mechanisms 6.3 Neurotransmitters, Learning & Behavioral Science
7 Musculoskeletal System
7.1 Bone Physiology, Fracture Healing & Bone Pathology 7.2 Joint Disease, Rheumatology & Connective Tissue 7.3 Muscle, NMJ & Peripheral Nerve Disorders
8 Skin & Soft Tissue
8.1 Dermatopathology High-Yield Lesions 8.2 Inflammation, Wound Healing & Soft-Tissue Infection
9 Cardiovascular Pathophysiology
9.1 Cardiac Cycle, Hemodynamics & Murmurs 9.2 Ischemic Heart Disease & Cardiomyopathy 9.3 Congenital & Valvular Heart Disease 9.4 Vascular Pathology & Hypertension
10 Cardiovascular Pharmacology
10.1 Antihypertensives, Heart Failure & Antiarrhythmics 10.2 Antiplatelets, Anticoagulants & Lipid Drugs
11 Respiratory System
11.1 Pulmonary Mechanics & Gas Exchange 11.2 Obstructive, Restrictive & Vascular Lung Disease 11.3 Pulmonary Infections, Neoplasms & Respiratory Pharmacology
12 Renal Physiology & Electrolytes
12.1 Nephron Transport & Renal Physiology 12.2 Electrolyte Disorders 12.3 Acid-Base Physiology & Compensation
13 Renal Pathology
13.1 Glomerular Disease Mechanisms 13.2 Tubulointerstitial, Vascular & Stone Disease
14 Gastrointestinal System
14.1 GI Physiology, Motility & Digestion 14.2 Esophagus, Stomach & Intestinal Pathology 14.3 Liver, Biliary Tree & Pancreas 14.4 GI Microbiology, Nutrition & Malabsorption
15 Endocrine System
15.1 Hormone Signaling & Hypothalamic-Pituitary Axes 15.2 Thyroid & Parathyroid Disease 15.3 Adrenal Disorders & Steroid Pharmacology 15.4 Diabetes, Glucose Homeostasis & Metabolic Syndrome
16 Reproductive System
16.1 Male & Female Reproductive Physiology 16.2 Pregnancy, Placenta & Developmental Toxicology 16.3 Reproductive Pathology & Hormone-Related Neoplasia
17 Multisystem Processes & Disorders
17.1 Cell Injury, Inflammation & Repair 17.2 Neoplasia Principles & Tumor Biology 17.3 Infection, Sepsis & Multisystem Microbial Disease 17.4 Genetics, Inborn Errors & Environmental Toxicology
18 Biostatistics & Epidemiology
18.1 Study Design, Bias & Causation 18.2 Diagnostic Test Metrics & Screening 18.3 Epidemiology Measures & Population Health
19 Social Sciences & Communication
19.1 Ethics Principles & Decision-Making Capacity 19.2 Communication Skills & Difficult Conversations 19.3 Professionalism, Systems & Practice-Based Learning
20 Integrated Disciplines Capstone
20.1 High-Yield Microbiology Anchors Across Systems 20.2 High-Yield Biochemistry & Molecular Mechanisms 20.3 Integrated Pharmacology Strategy & Exam-Day Execution
6.2 Psychopharmacology Mechanisms
Key Takeaways Explain This Topic AI
SSRIs block SERT; SNRIs block SERT and NET; TCAs add muscarinic, histaminergic, and α1 blockade plus sodium-channel toxicity in overdose; MAOIs inhibit monoamine breakdown and risk tyramine hypertensive crisis and serotonin syndrome.
Typical antipsychotics are high D2 antagonists with more EPS and hyperprolactinemia; atypicals add 5-HT2A antagonism with lower EPS risk but more metabolic adverse effects for several agents.
Neuroleptic malignant syndrome is severe rigidity, hyperthermia, autonomic instability, and elevated CK from profound D2 blockade; serotonin syndrome features hyperreflexia and clonus with serotonergic excess.
Lithium has a narrow therapeutic index with tremor, confusion, and seizures in toxicity; chronic use associates with hypothyroidism and nephrogenic diabetes insipidus.
Benzodiazepines positively modulate GABA-A receptors; valproate, carbamazepine, and lamotrigine stabilize mood through distinct ion-channel and signaling actions with agent-specific toxicities (hepatotoxicity/teratogenicity, agranulocytosis/autoinduction, SJS/TEN rash).
Last updated: August 2026
Antidepressants: Transporters, Enzymes, and Toxicities
SSRIs (fluoxetine, sertraline, citalopram/escitalopram, paroxetine, fluvoxamine) selectively inhibit the serotonin transporter ( SERT ), increasing synaptic 5-HT. Early adverse effects include GI upset, sexual dysfunction, and anxiety/activation; hyponatremia via SIADH is a high-yield systemic risk, especially in older adults. SNRIs (venlafaxine, duloxetine) inhibit SERT and the norepinephrine transporter ( NET ); venlafaxine can raise blood pressure at higher doses through NE effects. Duloxetine also appears in pain and neuropathy vignettes because of descending monoamine analgesia pathways.
Tricyclic antidepressants (TCAs) inhibit SERT and NET but also block muscarinic (anticholinergic: dry mouth, constipation, urinary retention, delirium), H1 (sedation, weight gain), and α1-adrenergic (orthostasis) receptors. Overdose is lethal via cardiac sodium-channel blockade (wide QRS, ventricular arrhythmias) plus anticholinergic and antihistaminic toxicity—sodium bicarbonate is the classic overdose antidote framing.
MAOIs (phenelzine, tranylcypromine, selegiline) inhibit monoamine oxidase, reducing intracellular breakdown of 5-HT, NE, and DA. Two exam-critical interactions dominate: (1) tyramine crisis —dietary tyramine normally metabolized by gut MAO-A enters the circulation when MAO is inhibited, releasing NE and causing hypertensive emergency; (2) serotonin syndrome when combined with SSRIs/SNRIs/meperidine/linezolid/triptans or other serotonergic drugs.
- Class Primary mechanism Signature toxicity / pearl
- SSRI SERT inhibition Sexual dysfunction; SIADH; serotonin syndrome risk
- SNRI SERT + NET inhibition Hypertension (esp. venlafaxine); serotonin syndrome risk
- TCA SERT/NET + mACh/H1/α1 block Wide-complex arrhythmia in overdose; anticholinergic effects
- MAOI MAO inhibition Tyramine hypertensive crisis; serotonin syndrome
- Bupropion DA/NE reuptake effects Seizure risk (dose/eating disorders); less sexual side effects
- Mirtazapine α2 antagonism → ↑5-HT/NE; H1 block Sedation, weight gain
Serotonin syndrome is excess 5-HT (often multi-drug): altered mental status, autonomic hyperactivity (hyperthermia, diaphoresis, tachycardia), and neuromuscular excitation with hyperreflexia and clonus (especially lower extremity). Contrast with NMS (below): NMS is bradyreflexic rigidity from dopamine blockade, not hyperreflexic clonus from serotonin excess.
Antipsychotics: D2, 5-HT2A, EPS, NMS, and Metabolic Effects
Typical (first-generation) antipsychotics (haloperidol, fluphenazine, chlorpromazine) primarily antagonize D2 receptors . High-potency agents (haloperidol) cause more extrapyramidal symptoms ( EPS ) and less H1/mACh/α1 blockade; low-potency agents (chlorpromazine, thioridazine) cause more sedation, anticholinergic effects, and orthostasis, with relatively less EPS. Atypical (second-generation) antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole, clozapine, ziprasidone) combine D2 antagonism (or partial agonism for aripiprazole) with 5-HT2A antagonism , generally reducing EPS at the cost of greater metabolic risk (weight gain, dyslipidemia, diabetes) for several agents—especially olanzapine and clozapine.
- Side-effect domain Mechanism Clinical pattern
- Acute dystonia Nigrostriatal D2 blockade Hours–days: torticollis, oculogyric crisis
- Akathisia D2-related motor restlessness Days–weeks: subjective need to move
- Parkinsonism Nigrostriatal D2 blockade Weeks: bradykinesia, rigidity, tremor
Tardive dyskinesia Chronic D2 blockade; receptor supersensitivity framing Months–years: choreoathetoid orofacial movements
Hyperprolactinemia Tuberoinfundibular D2 blockade Galactorrhea, amenorrhea, sexual dysfunction (risperidone high-yield)
- Metabolic syndrome H1/5-HT2C and other receptors Weight gain, insulin resistance (olanzapine, clozapine)
- Agranulocytosis Idiosyncratic (clozapine) Mandatory ANC monitoring
- QT prolongation Cardiac K-channel effects Arrhythmia risk (agent-dependent)
Neuroleptic malignant syndrome (NMS) is a life-threatening reaction to dopamine antagonists: severe “lead-pipe” rigidity , hyperthermia , autonomic instability, altered mental status, and elevated CK with possible rhabdomyolysis and renal failure. It is a hypodopaminergic state; management framing includes stop the agent, supportive care, and sometimes dantrolene or dopaminergic agents in clinical layers. Do not confuse with serotonin syndrome’s hyperreflexia/clonus.
Positive-symptom efficacy tracks mesolimbic D2 blockade. Worsening of negative symptoms or cognitive dulling can reflect mesocortical dopamine reduction—another reason pathway thinking beats “dopamine bad” heuristics.
Lithium: Efficacy, Toxicity, Thyroid, and Kidney
Lithium is a first-line mood stabilizer for mania and maintenance in bipolar disorder. Cellular mechanisms include inositol signaling modulation and effects on GSK-3 and second-messenger systems—exam items more often test pharmacokinetics and toxicity than every molecular target. Lithium is renally cleared, has a narrow therapeutic index , and toxicity is precipitated by dehydration, NSAIDs, ACE inhibitors, and thiazides that increase lithium levels.
Toxicity spectrum: tremor → ataxia, dysarthria, confusion → seizures and coma; ECG changes may appear. Chronic adverse effects include hypothyroidism (and goiter) and nephrogenic diabetes insipidus (downregulation of aquaporin-2 responsiveness to ADH → polyuria/polydipsia). Monitoring themes: serum levels, renal function, TSH, and pregnancy counseling (Ebstein anomaly risk is the classic teratogenicity association).
Benzodiazepines and GABA-A
Benzodiazepines bind an allosteric site on GABA-A receptors, increasing the frequency of chloride channel opening in the presence of GABA (positive allosteric modulation). Clinical effects: anxiolysis, sedation, muscle relaxation, anticonvulsant action. Risks include tolerance, dependence, respiratory depression especially with alcohol/opioids, and withdrawal seizures when stopped abruptly after chronic use. Flumazenil is a competitive antagonist used in select overdose settings but can precipitate seizures in dependent patients—mechanism awareness matters more than protocol memorization.
Stimulants
Amphetamines promote release and block reuptake of DA and NE; methylphenidate primarily blocks reuptake. They enhance prefrontal catecholamine signaling in ADHD. Adverse effects: appetite suppression, insomnia, tachycardia/hypertension, anxiety; misuse potential via mesolimbic reward activation. Atomoxetine (NET inhibitor) and α2 agonists (guanfacine, clonidine) are non-stimulant alternatives with different adverse-effect profiles (e.g., atomoxetine hepatotoxicity rare warning; α2 agonists cause sedation and hypotension).
Mood Stabilizers Beyond Lithium: Valproate, Carbamazepine, Lamotrigine
Agent Core mechanism framing Key toxicities / pearls
Valproate Na+ channel effects; ↑GABA; histone deacetylase inhibition themes Hepatotoxicity, pancreatitis, neural-tube defects (↓folate), weight gain, tremor, thrombocytopenia
Carbamazepine Voltage-gated Na+ channel blockade Agranulocytosis/aplastic anemia, SIADH/hyponatremia, CYP3A4 autoinduction, SJS risk (HLA-B*1502 in at-risk ancestry)
Lamotrigine Na+ channel modulation; glutamate release dampening Slow titration to avoid SJS/TEN ; safer in pregnancy than valproate for many bipolar depression contexts
Valproate is highly effective for acute mania and mixed features; lamotrigine is more associated with bipolar depression maintenance than acute mania. Carbamazepine’s enzyme induction creates drug–drug interaction vignettes. Always link rash timelines and titration speed for lamotrigine to immune-mediated severe cutaneous reactions.
Integrating Toxidromes for Exam Discrimination
- Syndrome Trigger class Motor findings Other anchors
- Serotonin syndrome Serotonergic combos Hyperreflexia, clonus Hyperthermia, diarrhea, agitation
- NMS Dopamine antagonists Lead-pipe rigidity, bradyreflexia High CK, days after start/increase
Anticholinergic toxicity TCAs, low-potency APs, antihistamines Normal reflexes; dry skin “Mad as a hatter…,” mydriasis, urinary retention
Lithium toxicity Lithium + renal clearance drop Coarse tremor, ataxia GI symptoms early; confusion, seizures
Psychopharmacology items reward receptor-level reasoning: if the vignette shows galactorrhea after risperidone, think tuberoinfundibular D2 blockade; if wide QRS after TCA overdose, think cardiac Na+ channels; if hypertensive crisis after cheese and an MAOI, think tyramine and peripheral NE; if hyperthermia with clonus after an SSRI plus MAOI, think serotonin syndrome rather than NMS.